Chemomab Therapeutics Ltd. Sponsored ADR CMMB

Chemomab Therapeutics reported second quarter 2026 financial results and issued a corporate update. Quarterly results and corporate updates can shift near-term investor views on financial position and plans.

Chemomab Therapeutics and Scipher Medicine announce merger agreement to advance Nebokitug in AI-powered Phase 2 rheumatoid arthritis trial. Merger enables AI-powered Phase 2 advancement of Nebokitug in rheumatoid arthritis and marks major strategic expansion.

Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) announced first quarter 2026 financial results and provided a corporate update. Quarterly financial results and corporate update affect key financial performance and investor sentiment without fundamentally altering long-term trajectory.

Chemomab Therapeutics announced year-end and fourth quarter 2025 financial results alongside a corporate update. Annual financial results and corporate update disclosure can significantly sway investor sentiment and stock trajectory for a clinical-stage biotech.

Chemomab Therapeutics Ltd. announced the publication of Phase 2 SPRING trial results for Nebokitug in treating Primary Sclerosing Cholangitis in the American Journal of Gastroenterology. The trial demonstrated promising efficacy and safety profiles, potentially positioning Nebokitug as a significant treatment option for this challenging condition. The publication is expected to enhance the visibility of Chemomab's research and development efforts in the gastroenterology field. The publication of positive trial results could significantly influence investor sentiment and the company's strategic positioning in the market.

Chemomab Therapeutics Ltd. will participate in Oppenheimer’s Movers in Rare Disease Summit, highlighting its focus on rare diseases and potential collaborations in this sector. The event is expected to provide insights into the company's strategies and innovations in addressing unmet medical needs. Participation in industry summits can enhance visibility and networking opportunities, potentially influencing future collaborations and market positioning.

Chemomab Therapeutics Ltd. reported its financial results for the third quarter of 2025, highlighting key metrics and developments in its corporate strategy. The company provided updates on ongoing clinical trials and future plans, emphasizing its commitment to advancing its therapeutic pipeline. Financial performance showed trends that may influence investor sentiment moving forward. The financial results and corporate updates indicate moderate influences on Chemomab's operational trajectory and market positioning.

Chemomab Therapeutics Ltd. announced multiple presentations at AASLD The Liver Meeting® 2025, showcasing clinical data from the Phase 2 trial of Nebokitug in patients with Primary Sclerosing Cholangitis. The presentations are expected to highlight the efficacy and safety of Nebokitug, contributing to the understanding of its potential benefits for patients suffering from this liver disease. The presentation of clinical data from a Phase 2 trial could significantly influence investor sentiment and the company's future trajectory in the liver disease market.

Efdoralprin Alfa, developed by SNY, has successfully met key endpoints in a study focused on a rare disease, indicating potential advancements in treatment options. This development may enhance SNY's position in the market and could have implications for related companies in the sector, including Chemomab Therapeutics Ltd. The successful study results may influence Chemomab's competitive positioning and market sentiment but are not expected to fundamentally alter its trajectory.

Chemomab Therapeutics Ltd. is focusing on diversifying its portfolio with a new candidate targeting rare liver diseases, which has led to a positive market response and an increase in stock value. The company's strategic move aims to enhance its position in the biopharmaceutical sector, potentially attracting investor interest and improving its competitive edge. The introduction of a new candidate for rare liver diseases is a significant strategic move that could enhance Chemomab's market position and investor sentiment.

Chemomab Therapeutics Ltd. announced that the FDA has accepted its resubmitted Biologics License Application (BLA) for a gene therapy product. This acceptance is a crucial step in the regulatory process, potentially paving the way for the therapy's approval and subsequent market entry. The news has positively impacted the stock price of Chemomab, reflecting investor optimism regarding the company's future prospects. FDA acceptance of the BLA is a significant regulatory milestone that could greatly influence Chemomab's market position and investor sentiment.

Chemomab Therapeutics Ltd. experienced a dramatic 84% drop in its stock price following the announcement that its Phase II study on fibrosis failed to meet key objectives. The disappointing results have raised concerns about the company's future prospects and its ability to advance its therapeutic pipeline. Investors reacted swiftly, leading to a significant decline in market confidence. The failure of a Phase II study is likely to have a significant impact on the company's future and market performance.

Chemomab Therapeutics Ltd. received FDA's Breakthrough Therapy designation for its CD388 treatment aimed at influenza, which is expected to expedite the development and review process. This designation highlights the potential of CD388 to address unmet medical needs in influenza treatment, potentially enhancing the company's market position and investor interest. The FDA's Breakthrough Therapy designation is likely to significantly impact Chemomab's future performance and investor sentiment by accelerating the development of a promising treatment.

Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) has experienced a significant decline in stock value, plummeting 88% over the past month following the failure of a study related to an eye disorder. The disappointing results have raised concerns about the company's future prospects and investor confidence. The failure of the eye disorder study is likely to have a significant impact on Chemomab's future performance and investor sentiment.

Chemomab Therapeutics Ltd. will present at the H.C. Wainwright 27th Annual Global Investment Conference, showcasing its advancements and strategic initiatives to potential investors and stakeholders. Participation in a significant investment conference may enhance visibility and investor interest, impacting market sentiment moderately.

Chemomab Therapeutics Ltd. reported its financial results for the second quarter of 2025, highlighting key metrics and developments in its corporate strategy. The company provided updates on ongoing clinical trials and future plans, emphasizing its commitment to advancing its therapeutic pipeline. Financial performance showed trends that may influence investor sentiment and market positioning. Financial results and updates on clinical trials may moderately influence Chemomab's market performance and investor sentiment.

Chemomab Therapeutics Ltd. announced positive Phase 2 clinical data for Nebokitug in treating Primary Sclerosing Cholangitis during the BSG Live’25 conference. The data highlights the drug's potential efficacy and safety, marking a significant step forward in addressing this challenging liver disease. The presentation is expected to enhance the company's visibility and credibility in the market. Positive clinical data from a Phase 2 trial can significantly influence investor sentiment and the company's future trajectory.

Chemomab Therapeutics Ltd. has received positive feedback from the FDA regarding its nebokitug program for primary sclerosing cholangitis (PSC). The FDA confirmed alignment on Chemistry, Manufacturing, and Controls (CMC) and allowed non-clinical toxicology studies to proceed in parallel with the Phase 3 clinical trial. CEO Adi Mor expressed optimism about advancing the program and ongoing discussions with potential strategic partners. Nebokitug, a monoclonal antibody targeting CCL24, has shown promise in treating PSC and has received Orphan Drug and Fast Track designations from the FDA. Positive FDA feedback and alignment on critical development milestones significantly enhance the prospects for nebokitug's advancement and potential market approval.

Chemomab Therapeutics has received new patent protections for its lead product, nebokitug, in China and Russia, extending coverage for its use in treating primary sclerosing cholangitis (PSC) until 2041. These patents enhance the company's intellectual property portfolio, which already includes protections in the U.S., Europe, and Japan. CEO Adi Mor highlighted the positive Phase 2 SPRING trial results and a clear FDA pathway for regulatory approval as significant advancements for nebokitug. The company is preparing for a Phase 3 trial in PSC, aiming for full regulatory approval. New patent protections and positive trial results significantly enhance Chemomab's strategic position and potential for regulatory approval.

Chemomab Therapeutics announced positive 48-week data from its SPRING trial for nebokitug in PSC patients, showing improvements in liver injury, inflammation, and fibrosis. The company has aligned with the FDA on a regulatory pathway for potential approval through a single pivotal Phase 3 trial. Cash runway extended to Q2 2026, and Chemomab is exploring strategic partnerships for the nebokitug program. Financial results for Q1 2025 showed a net loss of $3.3 million, with cash and equivalents at $10.6 million. The alignment with the FDA on a regulatory pathway and positive trial results are significant strategic moves that could greatly influence Chemomab's future performance.

Chemomab Therapeutics Ltd. announced positive Phase 2 clinical data for Nebokitug in treating Primary Sclerosing Cholangitis, presented at the distinguished plenary session during DDW 2025. The results indicate promising efficacy and safety profiles, potentially positioning Nebokitug as a significant treatment option in this challenging disease area. Positive clinical data could significantly enhance the company's product pipeline and market position in a critical therapeutic area.

Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) is experiencing a surge in search interest, indicating heightened investor attention. This spike may be linked to recent developments in the biotech sector, potentially influencing market sentiment and trading activity for the stock. Investors are closely monitoring the company's progress and any upcoming announcements that could impact its future performance. Increased search interest suggests a moderately noticeable influence on market sentiment and potential trading activity.

Chemomab Therapeutics, Ltd. announced positive clinical data for nebokitug (CM-101) at EASL 2025, showing significant improvements in inflammatory and fibrotic biomarkers in patients with primary sclerosing cholangitis (PSC) from the Phase 2 SPRING trial. The data supports nebokitug's potential as a first-in-class treatment for PSC and related diseases. Pharmacokinetic analyses indicated effective dose-dependent antibody-target engagement, correlating increased nebokitug levels with reduced PSC biomarkers. The company is preparing for a potential Phase 3 trial based on these findings. Positive clinical data and potential Phase 3 trial initiation could significantly enhance Chemomab's market position and investor sentiment.

Chemomab Therapeutics Ltd. will present clinical data on its drug Nebokitug at upcoming scientific conferences, highlighting advancements in its research and potential implications for treatment options. The presentation of clinical data at scientific conferences can significantly influence investor sentiment and the company's market position.

Chemomab Therapeutics has appointed David M. Weiner, MD, as Interim Chief Medical Officer and Jack Lawler as Chief Development Officer. Dr. Weiner, who previously served as CMO from 2021-2022, brings over 25 years of experience in drug development. Lawler, who oversaw the successful Phase 2 SPRING trial for nebokitug in primary sclerosing cholangitis (PSC), has 25 years of clinical drug development experience. The company is preparing for a potential Phase 3 trial for nebokitug, which has shown promise as a treatment for PSC and received FDA and EMA Orphan Drug designations. The leadership changes and upcoming Phase 3 trial for nebokitug are significant strategic moves that could greatly influence Chemomab's future performance.

Chemomab Therapeutics reported positive results from the Open Label Extension of the Phase 2 SPRING trial for nebokitug, a treatment for primary sclerosing cholangitis (PSC). After 48 weeks of treatment, patients showed significant improvements in liver biomarkers and a lower rate of clinical events compared to historical controls. The drug was well-tolerated, reinforcing its potential as the first approved disease-modifying therapy for PSC, which currently has no effective treatments. The results support the design of a planned Phase 3 clinical trial. Positive trial results for nebokitug could significantly alter Chemomab's trajectory and investor sentiment regarding its potential market approval.

Chemomab Therapeutics presented new data at the CORA 2025 conference, highlighting the potential of its monoclonal antibody nebokitug (CM-101) as a treatment for systemic sclerosis (SSc). The study, conducted with Dr. Alexandra Balbir-Gurman, demonstrated that nebokitug interferes with CCL24, a protein linked to SSc pathology. Preclinical evidence showed that blocking CCL24 reduced inflammation and fibrosis in SSc models. The findings support nebokitug's therapeutic rationale, especially following positive results from a Phase 2 trial in primary sclerosing cholangitis (PSC). Nebokitug has received FDA and EMA Orphan Drug designations and is being developed for SSc, with an open U.S. IND for a Phase 2 trial. The presentation of new clinical data and the ongoing development of nebokitug for systemic sclerosis could significantly impact Chemomab's future performance and investor sentiment.

Chemomab Therapeutics Ltd. announced positive results from its FDA End-of-Phase 2 meeting regarding nebokitug for treating primary sclerosing cholangitis (PSC), establishing a streamlined pathway for potential regulatory approval without the need for liver biopsies. The company reported financial results for 2024, showing a net loss of $13.9 million and a cash position of $14.3 million. Discussions with potential strategic partners are ongoing, and clinical data from the SPRING trial's open label extension is expected in Q1 2025. The alignment with the FDA on a streamlined approval pathway for nebokitug represents a significant strategic move that could alter Chemomab's market position and investor sentiment.

Chemomab Therapeutics Ltd. has successfully completed its End-of-Phase 2 Meeting with the FDA, aligning on a single Phase 3 trial design for nebokitug (CM-101) to treat primary sclerosing cholangitis (PSC). This pivotal trial will not require liver biopsies and will focus on clinically relevant endpoints associated with PSC progression. Approximately 350 patients will be enrolled, and the trial aims to demonstrate significant changes between treatment and placebo groups. The FDA's agreement on this trial design marks a significant milestone, potentially positioning nebokitug as the first FDA-approved treatment for PSC, addressing a high unmet medical need. Positive results from previous trials have bolstered confidence in nebokitug's efficacy and safety, with plans for a Phase 3 launch possibly before the end of the year. The FDA's alignment on a streamlined Phase 3 trial design for nebokitug represents a significant regulatory advancement that could lead to the first approved treatment for PSC.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced that CEO Dr. Adi Mor and senior management will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. The presentation will be webcast live and available for 90 days. Chemomab is developing CM-101, a monoclonal antibody targeting CCL24 for fibro-inflammatory diseases, with positive results from four clinical trials. The company anticipates achieving a clear FDA registrational pathway for a Phase 3 trial in primary sclerosing cholangitis (PSC) and reporting data from the SPRING trial open label extension in early 2025. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment. Upcoming milestones and positive trial results could significantly impact Chemomab's future performance and investor sentiment.